AstraZeneca blocks investor group's $7.6B buyout of rare disease specialist Sobi: report

After its $39 billion takeover of Alexion, AstraZeneca has reportedly scuppered an investor group's proposed buyout of another rare disease drugmaker. The company was worried one of its former respiratory meds could be sold to competitors, Bloomberg reports.

By holding back an 8% stake in Swedish Orphan Biovitrum (Sobi), AstraZeneca effectively repelled a $7.6 billion buyout of the rare disease specialist, Bloomberg reports, citing people close to the matter.